Shaping the Future of Cell-Based Medicine
Cellenvision is a team of biomedical experts from Taiwan.
Its core technology — an open system platform focusing on cell behavior and pathology for cancer diagnosis and treatment.
We can be
For
doctors
For doctors, a powerful tool can be used to diagnose cancer, guide treatment and predict patient survival.
For
cell therapy companies
For
GTP lab
For
LDT laboratories or hospitals
For LDT laboratories or hospitals, a unique platform leverages high-level inspection programs and value-added services.
Two Proprietary Technology Platforms
Personalized precision medication tumor immune microenvironment monitoring platform
– is a multifunctional platform that we have developed to combine Living Single Cells Microfluidic Capture Microdissection Microscopy and Al image recognition for longitudinal monitoring of tumor immune microenvironment (TiME) for the development of Immunotherapy Combination Strategies.
One-stop solution platform for personalized cell therapy
– is a total solution platform that we have developed to combine AI imaging + living cell monitoring microscopy + 3D printing + microfluidic system for Selections of Blood-TIL cells in blood by liquid biopsy, and co-cultured with primary cancer cells or CTM to dynamically monitor cytotoxicity efficacy for cell therapy or new drug development.
- • personalized precision medicine developing platform
- • Personalized cell therapy
- • Provide Clinical Decision Support and Clinical Trial
- • Management on immunological oncology
- • Provide Clinical Decision Support and Clinical Trial
- • Management on immunological oncology
- •AI-driven diagnostic tools
- •Organ on chip
- •Exosome-driven T cell therapy
Cell Envision, a startup based in Taiwan, has developed an innovative system that can improve patient survival rates facing the dangers of cancer, together with enhancements in reproductive medicine.
For medical LDT lab test and IVD (companion diagnostics) medical devices applied for Personalized Cancer Immunotherapy. We are accelerating the discovery of identification & pathogenesis in reproductive medicine and oncology by revealing the true functional biology of every patient rare cell and its related immuno-microenvironment by our unique Patient-Derived Organoids (PDOs) platform.
CellEnvision Named Top 15 in Taiwan Startup World Cup
In September 2025, Cell Envision Biotech was selected as one of the Top 15 finalists in the Taiwan Startup World Cup, emerging from a highly competitive pool of over a hundred startup teams. This comp
CellEnvision Named Top 15 in Taiwan Startup World Cup
In September 2025, Cell Envision Biotech was selected as one of the Top 15 finalists in the Taiwan Startup World Cup, emerging from a highly competitive pool of over a hundred startup teams. This comp
Instrument and
Reagent Kit
Rare cell reagent Kit: Sign I test microfluidic chip
Instrument and
Reagent Kit
Rare cell reagent Kit:
Sign I test microfluidic chip
- Our Global Partners
With patents approved in the United States (UChicago Medicine), Europe (Gustave Roussy Cancer Centre, France), Asia (Tokyo University; Institute of Information Technology and Management, Indian), and Taiwan, Cell Envision hopes to deliver even more positive results in the biotech field. The company has recently closed its seed funding round and will look to new territories like Europe and the United States following its presence in Asia.